BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210827
DTSTAMP:20260515T205416
CREATED:20210507T084054Z
LAST-MODIFIED:20210507T084054Z
UID:30057-1629763200-1630022399@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Alzheimer’s Disease Summit
DESCRIPTION:The 2nd Annual Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement. \nBack for its 2nd year\, there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape. This industry-defining meeting delves into blood-based biomarkers\, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge\, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s Disease. \nThe Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science\, convey lessons learned and network to build long lasting partnerships. \nTo know more about 2nd Annual Biomarkers for Alzheimer’s Disease Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-alzheimers-disease-summit/
LOCATION:Online Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210827
DTSTAMP:20260515T205416
CREATED:20210602T122800Z
LAST-MODIFIED:20210602T122800Z
UID:30421-1629763200-1630022399@www.pharmajournalist.com
SUMMARY:PI3K Therapies Summit
DESCRIPTION:With 5 currently approved PI3K inhibitors in the market\, and countless investments\, M&As and candidates entering the clinical stages\, the PI3K pathways space has experienced significant growth in recent years. \nThe inaugural PI3K Pathways Summit is the industry’s only definitive conference providing in depth exploration of the biochemical basis of the pathway\, the successes and setbacks in gaining approval for PI3K inhibitors and the future advances which will potentially aid in overcoming issues with tolerability\, toxicity and resistance associated with PI3K inhibitors. \nJoin the online discussion at the only digital platform dedicated to bringing together the community of PI3K experts from large pharma\, innovative biotechs and research institutes for a unique opportunity to address the challenges of targeting the PI3K and AKT pathway\, evaluate strategies for overcoming these challenges to define next generation PI3K drugs and participate in cross-disciplinary discussions with fellow industry peers.
URL:https://www.pharmajournalist.com/event/pi3k-therapies-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210825
DTEND;VALUE=DATE:20210828
DTSTAMP:20260515T205416
CREATED:20210514T085007Z
LAST-MODIFIED:20210514T085007Z
UID:30162-1629849600-1630108799@www.pharmajournalist.com
SUMMARY:5th IPF Summit
DESCRIPTION:Overcome Translational & Clinical Challenges to Develop Disease-Modifying Drugs for IPF\, the Archetypal Fibrotic Disease. From Dissecting Mechanisms of Epithelial Dysfunction to Discovering Patient Reported Outcomes for More Meaningful Clinical Trials\, Uncover Scientific Advancements & Actionable Insights to Optimize IPF Drug Development. \nReturning with a revitalized agenda including 25 brand new speakers\, the hotly anticipated two-tracked summit is back! \nAs epithelial targets return to the limelight\, innovations in translational models hit their stride and clinical trial competition dramatically heats up; there’s more translational and clinically relevant science for IPF now than ever before\, catapulting this archetypal fibrotic disease right to the top of biopharma’s priority list. \n \nDedicated to providing you with the insights you need to create clinically defining IPF therapeutics\, this premier industry forum will unite industry experts from AstraZeneca\, Genentech\, Ionis\, AbbVie\, Gilead\, Lassen Therapeutics\, Pliant\, Galecto and more with leading academia\, for you to gain back-to-back insights on the science propelling IPF drug development forward. \nFrom dissecting the fibrotic lung microenvironment and comprehensively analyzing multiple translational models alongside bleomycin to including patient-reported outcomes as an endpoint in clinical trials; the 5th IPF Summit is the only end-to-end forum presenting scientific advancements as actionable insights for more innovative and clinically effective drug development. \nAs organizations across fibrosis\, autoimmunity and inflammatory disease turn their heads towards IPF in a bid to capitalize on its strategic opportunity\, Join 150+ IPF drug developers this August at this unique forum for a dynamic mix of formal presentations\, audience discussions\, panel discussions and organized networking and leave with the expertise your team needs to optimize your IPF R&D for 2021 and beyond. \nWant to learn more about our brand new 2021 agenda and expert speaker faculty? Click Here 
URL:https://www.pharmajournalist.com/event/5th-ipf-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR